German pharma Grünenthal has began the method of taking possession of 13 ageing medicines developed by Japan’s Kyowa Kirin, that are at the moment bought by affiliate firms throughout Europe.
The primary stage of the rights switch is the formation of a three way partnership between the 2 firms – 51% owned by Grünenthal – that may have rights to the manufacturers, which have annual revenues of round €200 million ($207 million) a yr.
In early 2026, Grünenthal intends to purchase out the remaining stake within the JV to say full management of the merchandise, which embrace fentanyl-based merchandise Abstral and PecFent for breakthrough most cancers ache, Moventig (naloxegol) for opioid-induced constipation, and dietary complement Adcal-D3 for osteoporosis.
The privately-held firm is paying €80 million upfront to Kyowa Kirin, which can be in line for royalties over the time period of the collaboration and a last, undisclosed cost when the present relationship ends. Grünenthal’s personal revenues have been round €1.5 billion in 2021.
The ache merchandise complement the German drugmaker’s present portfolio which features a topical capsaicin product referred to as Qutenza for post-shingles nerve ache and diabetic nerve ache affecting the ft, together with non-opioid analgesic resiniferatoxin which lately superior into part 3 testing in sufferers with osteoarthritis.
“As a pacesetter in ache administration, and with our confirmed monitor file in rising established manufacturers, we imagine we might help much more sufferers profit from this distinctive group of medicines,” stated Gabriel Baertschi, Grünenthal’s chief government (pictured above).
“This portfolio of established manufacturers matches very nicely with Grünenthal’s geographical footprint and therapeutic areas,” he added.
The German firm is not any stranger to rising its portfolio by shopping for older manufacturers, having invested €2 billion in M&A transactions within the final couple of years.
Jut a couple of weeks in the past it closed the acquisition of testosterone alternative remedy Nebido for male hypogonadism from Bayer in European and Latin American markets, in return for a cost of €495 million.
Earlier offers included taking rights to ldl cholesterol drug Crestor, gastrointestinal illness remedy Nexium (esomeprazole), migraine remedy Zomig (zolmitriptan), and anti inflammatory drug Vimovo (naproxen/esomeprazole) from AstraZeneca, in addition to possession of Qutenza from Acorda Therapeutics.
And final yr, its acquisition of Swiss biotech firm Mestex for an undisclosed sum added resiniferatoxin to its pipeline.